Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Hepatologists’ Awareness and Knowledge of NAFLD and the Familiarity with Renaming NAFLD to MAFLD

Author(s): Shereen Abdel Alem, Yasser Fouad, Mohamed AbdAllah, Dina Attia, Inas Kamal, Ebada Said, Ahmed Gomaa, Sherief M. Abd-Elsalam* and Yasmine Gaber*

Volume 24, Issue 12, 2024

Published on: 08 May, 2024

Page: [1445 - 1453] Pages: 9

DOI: 10.2174/1871530323666221028154159

Price: $65

conference banner
Abstract

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is an emerging epidemic; it is a negative diagnosis that depends mainly on the presence of hepatic steatosis with or without inflammation after the exclusion of other chronic liver diseases and excess alcohol intake. However, the new definition of MAFLD is a shift towards a diagnosis of inclusion based on the presence of metabolic dysfunction, regardless of alcohol consumption or other concomitant liver diseases. Given the growing relevance of the disease, data on hepatologists' views and understanding of NAFLD are limited, we aimed to determine hepatologists' awareness and expertise of NAFLD screening, diagnosis, and therapeutic options as well as the influence of changing the NAFLD name to MAFLD on awareness of the fatty liver disease (FLD).

Objective: Most of the hepatologists agreed that NAFLD can cause serious hepatic illness and may be linked to metabolic risk factors, necessitating a multidisciplinary approach to treatment. Hepatologists have a poor understanding of NAFLD care. The shift in terminology from NAFLD to MAFLD will be more known to hepatologists, and it may offer better awareness of FLD.

Methods: A multicenter online questionnaire of 655 hepatologists was carried out, giving a sample of 207 respondents. A survey composed of 36 questions was used to assess the level of hepatologists' awareness and practices in the screening, diagnosis, and management of NAFLD/MAFLD, as well as their familiarity with the nomenclature change from NAFLD to MAFLD.

Results: A total of 207 hepatologists were included, of which 107 (51.4%) were males, with a mean age was 36.4 years. 50.2% (n = 104) of the hepatologists were oriented with NAFLD. Only 41 (19.8%) realized that NAFLD may frequently result in severe hepatic disease. NAFLD is rarely screened by the majority of the participating hepatologists (118, 57%), and (135, 65.2%) of them use liver biopsy for diagnosis of NAFLD. In (104, 50.2%) hepatologists, changing the nomenclature of NAFLD was relatively familiar. Furthermore, 71.9% of hepatologists thought that the new nomenclature offers a better awareness of FLD.

Conclusion: A small percentage of hepatologists agreed that NAFLD can cause serious hepatic illness and may be linked to metabolic risk factors, and around half of them realize that NAFLD necessitates a multidisciplinary approach to treatment. Hepatologists have a poor understanding of NAFLD care. The shift in terminology from NAFLD to MAFLD will be more known to hepatologists, and it may offer better awareness of FLD.

Keywords: Awareness, FLD awareness, metabolic-associated fatty liver disease, non-alcoholic fatty liver disease, liver, hepatologists, hepatic steatosis.

« Previous Next »
Graphical Abstract

[1]
Perumpail, B.J.; Khan, M.A.; Yoo, E.R.; Cholankeril, G.; Kim, D.; Ahmed, A. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J. Gastroenterol., 2017, 23(47), 8263-8276.
[http://dx.doi.org/10.3748/wjg.v23.i47.8263] [PMID: 29307986]
[2]
Lazarus, J.V.; Colombo, M.; Cortez, P.H.; Huang, T.T.K.; Miller, V.; Ninburg, M.; Schattenberg, J.M.; Seim, L.; Wong, V.W.S.; Zelber, S.S. NAFLD — sounding the alarm on a silent epidemic. Nat. Rev. Gastroenterol. Hepatol., 2020, 17(7), 377-379.
[http://dx.doi.org/10.1038/s41575-020-0315-7] [PMID: 32514153]
[3]
Eslam, M.; Sanyal, A.J.; George, J.; Sanyal, A.; Neuschwander, T.B.; Tiribelli, C.; Kleiner, D.E.; Brunt, E.; Bugianesi, E.; Yki, J.H.; Grønbæk, H.; Cortez, P.H.; George, J.; Fan, J.; Valenti, L.; Abdelmalek, M.; Romero, G.M.; Rinella, M.; Arrese, M.; Eslam, M.; Bedossa, P.; Newsome, P.N.; Anstee, Q.M.; Jalan, R.; Bataller, R.; Loomba, R.; Sookoian, S.; Sarin, S.K.; Harrison, S.; Kawaguchi, T.; Wong, V.W.S.; Ratziu, V.; Yilmaz, Y.; Younossi, Z. International consensus panel. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158(7), 1999-2014.e1.
[http://dx.doi.org/10.1053/j.gastro.2019.11.312] [PMID: 32044314]
[4]
Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol., 2018, 15(1), 11-20.
[http://dx.doi.org/10.1038/nrgastro.2017.109] [PMID: 28930295]
[5]
Sarin, S.K.; Kumar, M.; Eslam, M.; George, J.; Al Mahtab, M.; Akbar, S.M.F.; Jia, J.; Tian, Q.; Aggarwal, R.; Muljono, D.H.; Omata, M.; Ooka, Y.; Han, K.H.; Lee, H.W.; Jafri, W.; Butt, A.S.; Chong, C.H.; Lim, S.G.; Pwu, R.F.; Chen, D.S. Liver diseases in the Asia-Pacific region: A lancet gastroenterology & hepatology commission. Lancet Gastroenterol. Hepatol., 2020, 5(2), 167-228.
[http://dx.doi.org/10.1016/S2468-1253(19)30342-5] [PMID: 31852635]
[6]
Byrne, C.D.; Targher, G. NAFLD: A multisystem disease. J. Hepatol., 2015, 62(Suppl.), S47-S64.
[http://dx.doi.org/10.1016/j.jhep.2014.12.012] [PMID: 25920090]
[7]
Jepsen, P.; Vilstrup, H.; Mellemkjaer, L.; Thulstrup, A.M.; Olsen, J.H.; Baron, J.A.; Sørensen, H.T. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology, 2003, 50(54), 2101-2104.
[PMID: 14696473]
[8]
Sørensen, H.T.; Mellemkjær, L.; Jepsen, P.; Thulstrup, A.M.; Baron, J.; Olsen, J.H.; Vilstrup, H. Risk of cancer in patients hospitalized with fatty liver: A Danish cohort study. J. Clin. Gastroenterol., 2003, 36(4), 356-359.
[http://dx.doi.org/10.1097/00004836-200304000-00015] [PMID: 12642745]
[9]
Liu, D.; Shen, Y.; Zhang, R.; Xun, J.; Wang, J.; Liu, L.; Steinhart, C.; Chen, J.; Lu, H. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China. J. Gastroenterol. Hepatol., 2021, 36(6), 1670-1678.
[http://dx.doi.org/10.1111/jgh.15320] [PMID: 33140878]
[10]
Eslam, M.; Newsome, P.N.; Sarin, S.K.; Anstee, Q.M.; Targher, G.; Romero, G.M.; Zelber, S.S.; Wai, S.W.V.; Dufour, J.F.; Schattenberg, J.M.; Kawaguchi, T.; Arrese, M.; Valenti, L.; Shiha, G.; Tiribelli, C.; Yki, J.H.; Fan, J.G.; Grønbæk, H.; Yilmaz, Y.; Cortez, P.H.; Oliveira, C.P.; Bedossa, P.; Adams, L.A.; Zheng, M.H.; Fouad, Y.; Chan, W.K.; Mendez, S.N.; Ahn, S.H.; Castera, L.; Bugianesi, E.; Ratziu, V.; George, J. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol., 2020, 73(1), 202-209.
[http://dx.doi.org/10.1016/j.jhep.2020.03.039] [PMID: 32278004]
[11]
de Silva, H.J.; Dassanayake, A.S. Non-alcoholic fatty liver disease: Confronting the global epidemic requires better awareness. J. Gastroenterol. Hepatol., 2009, 24(11), 1705-1707.
[http://dx.doi.org/10.1111/j.1440-1746.2009.06026.x] [PMID: 20136955]
[12]
Younossi, Z.M. Non-alcoholic fatty liver disease – A global public health perspective. J. Hepatol., 2019, 70(3), 531-544.
[http://dx.doi.org/10.1016/j.jhep.2018.10.033] [PMID: 30414863]
[13]
Chalasani, N.; Younossi, Z.; Lavine, J.E.; Charlton, M.; Cusi, K.; Rinella, M.; Harrison, S.A.; Brunt, E.M.; Sanyal, A.J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the study of liver diseases. Hepatology, 2018, 67(1), 328-357.
[http://dx.doi.org/10.1002/hep.29367] [PMID: 28714183]
[14]
Lonardo, A.; Nascimbeni, F.; Targher, G.; Bernardi, M.; Bonino, F.; Bugianesi, E.; Casini, A.; Gastaldelli, A.; Marchesini, G.; Marra, F.; Miele, L.; Morisco, F.; Petta, S.; Piscaglia, F.; Svegliati-Baroni, G.; Valenti, L.; Bellentani, S. AISF position paper on Nonalcoholic Fatty Liver Disease (NAFLD): Updates and future directions. Dig. Liver Dis., 2017, 49(5), 471-483.
[http://dx.doi.org/10.1016/j.dld.2017.01.147] [PMID: 28215516]
[15]
Corey, K.E.; Klebanoff, M.J.; Tramontano, A.C.; Chung, R.T.; Hur, C. Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: A cost-effectiveness analysis. Dig. Dis. Sci., 2016, 61(7), 2108-2117.
[http://dx.doi.org/10.1007/s10620-016-4044-2] [PMID: 26825843]
[16]
Bergqvist, C.J.; Skoien, R.; Horsfall, L.; Clouston, A.D.; Jonsson, J.R.; Powell, E.E. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern. Med. J., 2013, 43(3), 247-253.
[http://dx.doi.org/10.1111/j.1445-5994.2012.02848.x] [PMID: 22646061]
[17]
Ratziu, V.; Cadranel, J.F.; Serfaty, L.; Denis, J.; Renou, C.; Delassalle, P.; Bernhardt, C.; Perlemuter, G. A survey of patterns of practice and perception of NAFLD in a large sample of practicing gastroenterologists in France. J. Hepatol., 2012, 57(2), 376-383.
[http://dx.doi.org/10.1016/j.jhep.2012.03.019] [PMID: 22521354]
[18]
European Association for the Study of Liver. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 2016, 64(6), 1388-1402.
[http://dx.doi.org/10.1016/j.jhep.2015.11.004] [PMID: 27062661]
[19]
Palmentieri, B.; Desio, I.; Lamura, V.; Masarone, M.; Vecchione, R.; Bruno, S.; Torella, R.; Persico, M. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig. Liver Dis., 2006, 38(7), 485-489.
[http://dx.doi.org/10.1016/j.dld.2006.03.021] [PMID: 16716779]
[20]
Dasarathy, S.; Dasarathy, J.; Khiyami, A.; Joseph, R.; Lopez, R.; McCullough, A.J. Validity of real time ultrasound in the diagnosis of hepatic steatosis: A prospective study. J. Hepatol., 2009, 51(6), 1061-1067.
[http://dx.doi.org/10.1016/j.jhep.2009.09.001] [PMID: 19846234]
[21]
EASL-ALEH clinical practice guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J. Hepatol., 2015, 63(1), 237-264.
[http://dx.doi.org/10.1016/j.jhep.2015.04.006] [PMID: 25911335]
[22]
Wessels, D.H.; Rosenberg, Z. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us? World J. Hepatol., 2021, 13(2), 233-241.
[http://dx.doi.org/10.4254/wjh.v13.i2.233] [PMID: 33708352]
[23]
Grattagliano, I.; D’Ambrosio, G.; Palmieri, V.O.; Moschetta, A.; Palasciano, G.; Portincasa, P. Improving nonalcoholic fatty liver disease management by general practitioners: A critical evaluation and impact of an educational training program. J. Gastrointestin. Liver Dis., 2008, 17(4), 389-394.
[PMID: 19104698]
[24]
VanWagner, L.B.; Rinella, M.E. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr. Hepatol. Rep., 2016, 15(2), 75-85.
[http://dx.doi.org/10.1007/s11901-016-0295-9] [PMID: 27218012]
[25]
Ong, J.P.; Pitts, A.; Younossi, Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol., 2008, 49(4), 608-612.
[http://dx.doi.org/10.1016/j.jhep.2008.06.018] [PMID: 18682312]

Rights & Permissions Print Cite
Article Metrics
16
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy